US20230338675A1 - Pressure barrier drug delivery device - Google Patents
Pressure barrier drug delivery device Download PDFInfo
- Publication number
- US20230338675A1 US20230338675A1 US18/189,129 US202318189129A US2023338675A1 US 20230338675 A1 US20230338675 A1 US 20230338675A1 US 202318189129 A US202318189129 A US 202318189129A US 2023338675 A1 US2023338675 A1 US 2023338675A1
- Authority
- US
- United States
- Prior art keywords
- pressurized fluid
- dispensing device
- fluid source
- internal volume
- pressure chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004888 barrier function Effects 0.000 title claims 9
- 238000012377 drug delivery Methods 0.000 title description 2
- 230000009286 beneficial effect Effects 0.000 claims abstract description 17
- 230000004913 activation Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims 40
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 2
- 239000001569 carbon dioxide Substances 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000000463 material Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013022 venting Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229940065778 narcan Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0035—Piercing means
- A61M15/0036—Piercing means hollow piercing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/004—Details of the piercing or cutting means with fixed piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0063—Storages for pre-packed dosages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6063—Optical identification systems
- A61M2205/6081—Colour codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8218—Gas operated
- A61M2205/8225—Gas operated using incorporated gas cartridges for the driving gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
Definitions
- the present disclosure generally relates to dispensing packages. More specifically, the disclosure relates to intranasal drug delivery devices.
- Intranasal dispensers such as those used to administer Narcan®, utilize manual force to create a spray or jet of beneficial agent contained in the device. This results in potential variation in the dispensed flow characteristics depending on how strong and/or how fast the dispenser is operated. This irregularity in the flow characteristics may also result in varying drug absorbance and effectiveness.
- Previously known intranasal dispensers use a syringe style form factor (i.e., barrel and piston arrangement).
- a syringe style form factor i.e., barrel and piston arrangement.
- One drawback of such dispensers is that the exposure of the beneficial agent with materials associated with syringes such as silicone and rubber may compromise the beneficial agent’s stability and effectiveness. Glass syringes can also compromise the device’s tolerance to impact.
- FIG. 1 a is an elevational view of an intranasal dispenser according to an exemplary embodiment, and showing the dispenser in a pre activation configuration;
- FIG. 1 b is a cross-sectional view of the intranasal dispenser as viewed about line 1b-1b in FIG. 1 a ;
- FIG. 2 a is an elevational view of the intranasal dispenser in an activated configuration
- FIG. 2 b is a cross-sectional view of the intranasal dispenser as viewed about line 2b-2b in FIG. 2 a ;
- FIG. 3 a is a perspective view of an intranasal dispenser with having a telescopic body
- FIG. 3 b is a perspective view of the intranasal dispenser of FIG. 3 b and showing its cap removed.
- a beneficial agent dispenser comprising a body and at least one dispensing port.
- a pressure chamber is located in the body.
- Beneficial agent is stored in a flexible primary container located within the body.
- the primary container may be a blister pack made from at least one of a film and a foil.
- Pressure in the pressure chamber depresses the primary container causing the beneficial agent to expel through the dispensing port.
- a pressure source causes the pressure chamber to pressurize.
- the pressure source is a relatively small CO 2 cartridge having a rupturable membrane.
- a rupturable pin may be located in front of the rupturable membrane. The rupturing pin ruptures the rupturable membrane when the two are moved toward each other in a relative motion.
- a handle associated with an activation mechanism may be used to initiate the relative motion to rupture the CO 2 cartridge and pressurize the pressure chamber.
- the primary container may be a flexible or semi-flexible package including, e.g., molded containers, blow molded containers, a sachet, a pouch, a tube, or any combination thereof.
- the dispensing port may be configured for a variety of applications including, topical, oral, sub-lingual, ocular, oraticular, and for inhalation.
- the dispensing port may be of a variety of forms, including, e.g., a jet nozzle, a spray nozzle, or a topical applicator such as a brush or sponge.
- Pressure sources other than CO 2 cartridges may be used, including pressure sources wherein pressure results from a chemical reaction.
- the disclosed dispenser includes multiple primary containers containing the same or different beneficial agents.
- the primary container comprises multiple compartments that can be manually or automatically merged prior to administration.
- a first compartment comprises an active ingredient in dry format and a second compartment comprises a diluent, and the two compartments are merged prior to administration to allow the two substances to reconstitute and form the beneficial agent.
- the disclosed dispenser may comprise multiple primary containers, with the contents of each being dispensed through a common dispensing port.
- the disclosed dispenser includes multiple primary containers, the content of each is dispensed from a different dispensing port
- FIG. 1 a illustrates an intranasal dispenser 100 according to various embodiments described herein.
- Intranasal dispenser 100 can include a body 111 , a cap 113 attached to the body 111 at a proximal end 114 , and an activation handle 112 .
- the activation handle 112 communicates with an activation mechanism 102 ( FIG. 1 b ).
- FIG. 1 b illustrates a cross section view of the intranasal dispenser 100 taken along line 1b-1b shown in FIG. 1 a .
- the dispenser 100 includes a pressure chamber 110 within the body 111 .
- the dispenser 100 further includes a CO 2 cartridge 121 , wherein a distal end confronts a rupturing pin 122 .
- the distal end of the cartridge 121 communicates with an activation mechanism 102 , which can be manipulated by the handle 112 .
- a piston 125 defines a proximal end of the pressure chamber 110 and is moveable between a pre-activation position (shown in FIG. 1 b ) and an activated position (shown in FIG. 2 b ).
- a first primary container 123 is located in the pressure chamber 110 and is connected to the piston 125 .
- more than one primary container 123 can be located within the body 111 , though FIG. 1 b shows a single primary container 123 .
- the primary container 123 is a blister pack made of a formed side, a lid, a flat side, and a fitment 124 .
- the formed side and the lid side are peripherally sealed to each other, and each to the fitment 124 to form a sealed compartment.
- the fitment 124 is accommodated in an opening in the piston 125 in a seal tight fashion via seal 126 .
- a piston seal 128 maintains a sealed connection between the piston 125 and the body 111 .
- Venting windows 127 prevent pressure from building in the proximal end of the body 111 .
- a dispensing port 132 (shown in FIG. 1 b in the form of a two-prone nasal applicator) extend from the body 111 .
- a tube 131 runs inside the dispensing port 132 and communicates between the interior of the body 111 and the proximal end of the dispensing port 132 .
- Cap 113 provides at least one of physical protection and aseptic enclosure to the dispensing port 132 .
- FIG. 2 a illustrates the intranasal dispenser 100 in an activated position.
- the handle 112 is rotated away from the body 111 to draw back the activation mechanism 102 , then depressed toward the body 111 to cause the activation mechanism 102 to rupture the CO 2 cartridge 121 against the rupturing pin 122 and thereby pressurize the pressure chamber 110 .
- the cap 113 is removed to expose the dispensing port 132 .
- the activation mechanism 102 advances the CO 2 cartridge 121 such that the rupturing pin 122 is penetrated into the cartridge 121 , allowing the CO 2 gas to pressurize the pressure chamber 110 .
- the pressure advances the piston 125 toward the proximal end of the dispenser 100 , to the activated position, causing the distal end of the tube 131 to penetrate the primary container 123 , allowing the pressure to depress the primary container 123 and expel the content of the primary container 123 through the dispensing port 132 .
- the seal 128 shows in the venting window 127 , indicating that the device 100 has been actuated.
- a bleed hole opens when the seal 128 reaches the activated position, allowing the gas from the pressure chamber 110 to deplete and reduce the pressure.
- a piston return spring (not shown) is disposed in vented chamber 130 ( FIG. 1 b ), and the arrangement is such that after activation, when the pressure in the pressure chamber 110 is depleted under a certain threshold pressure, the spring force overcomes the force applied by the pressure in the pressure chamber 110 , causing the piston 125 to retract and detach from the piston seal 128 .
- the bleed hole serves as a timer for the piston dwelling time at the activated position such that faster bleed (e.g.
- FIGS. 3 a and 3 b illustrate an intranasal dispenser 300 similar to the intranasal dispenser 100 , comprising a telescopic body 301 .
- a tether 304 is attached to the cap 303 on one end and a carabiner 305 on its other end.
- FIG. 3 a illustrates the dispenser 300 when the body is collapsed which may be more convenient for storage.
- the telescopic body By holding the telescopic body 301 and pulling the tether 304 in the opposite direction of the body 301 , the telescopic body extends in an axial direction while the cap 305 is removed to expose the dispensing port 321 , as shown in FIG. 3 b .
- the arrangement is such that the proximal end of the telescopic body 301 covers the distal end of the cap, preventing the cap from being removed until the body 301 is extended. At the extended position the handle 312 is allowed to move to the armed position for activation.
- the tether 304 is printed with information to facilitate user training and operation.
- the distal portion of the body 301 is color coded to distinguish the dispenser 300 from other dispensers of different medications.
- at least one of the tether 304 , the cap 303 , and the carabiner 305 can be color coded.
- the distal end 302 of the body 301 can have a distinguished shape to help identify the treatment.
- the dispenser 300 facilitates operation of the dispenser 300 with limited dexterity or when wearing gloves as the extended body 301 provides better gripping of the device, and the tether 304 with the carabiner 305 allows for easier holding and pulling than holding the cap 303 directly.
- the carabiner 305 can be attached to a firm object such as a garment, a carrying case or a bag, and the extension of the body 301 is done by merely pulling the telescopic body 301 .
- Details of the treatment can be printed on or attached to at least one of the tether 304 , carabiner 305 , or the cap 303 .
- the carabiner 305 can be attached to the garment of a subject to indicate that the subject has been treated.
- a stated range of 1 to 10 should be considered to include and provide support for claims that recite any and all sub-ranges or individual values that are between and/or inclusive of the minimum value of 1 and the maximum value of 10; that is, all sub-ranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 5.5 to 10, 2.34 to 3.56, and so forth) or any values from 1 to 10 (e.g., 3, 5.8, 9.9994, and so forth).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Mechanical Engineering (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
A beneficial agent dispensing device comprises a dispenser body comprising a pressure chamber and at least one dispensing port. A flexible primary container stores the beneficial agent contained within the body. The arrangement is such that pressure in the pressure chamber depress the flexible primary container to expel the beneficial agent through the dispensing port. The beneficial agent dispenser can be configured to deliver the beneficial agent intranasally.
Description
- This application claims the benefit of U.S. Provisional Pat. Application No. 62/749,296 filed Oct. 23, 2018 and is incorporated herein by reference in its entirety.
- The present disclosure generally relates to dispensing packages. More specifically, the disclosure relates to intranasal drug delivery devices.
- Intranasal dispensers, such as those used to administer Narcan®, utilize manual force to create a spray or jet of beneficial agent contained in the device. This results in potential variation in the dispensed flow characteristics depending on how strong and/or how fast the dispenser is operated. This irregularity in the flow characteristics may also result in varying drug absorbance and effectiveness.
- Previously known intranasal dispensers use a syringe style form factor (i.e., barrel and piston arrangement). One drawback of such dispensers is that the exposure of the beneficial agent with materials associated with syringes such as silicone and rubber may compromise the beneficial agent’s stability and effectiveness. Glass syringes can also compromise the device’s tolerance to impact.
- Accordingly, a need exists for improved intranasal dispensers that address some or all of the issued discussed above.
-
FIG. 1 a is an elevational view of an intranasal dispenser according to an exemplary embodiment, and showing the dispenser in a pre activation configuration; -
FIG. 1 b is a cross-sectional view of the intranasal dispenser as viewed aboutline 1b-1b inFIG. 1 a ; -
FIG. 2 a is an elevational view of the intranasal dispenser in an activated configuration; -
FIG. 2 b is a cross-sectional view of the intranasal dispenser as viewed aboutline 2b-2b inFIG. 2 a ; -
FIG. 3 a is a perspective view of an intranasal dispenser with having a telescopic body; and -
FIG. 3 b is a perspective view of the intranasal dispenser ofFIG. 3 b and showing its cap removed. - Described herein are various embodiments of a beneficial agent dispenser comprising a body and at least one dispensing port. A pressure chamber is located in the body. Beneficial agent is stored in a flexible primary container located within the body. In some embodiments, the primary container may be a blister pack made from at least one of a film and a foil. Pressure in the pressure chamber depresses the primary container causing the beneficial agent to expel through the dispensing port. A pressure source causes the pressure chamber to pressurize. In some embodiments, the pressure source is a relatively small CO2 cartridge having a rupturable membrane. A rupturable pin may be located in front of the rupturable membrane. The rupturing pin ruptures the rupturable membrane when the two are moved toward each other in a relative motion. A handle associated with an activation mechanism may be used to initiate the relative motion to rupture the CO2 cartridge and pressurize the pressure chamber.
- The primary container may be a flexible or semi-flexible package including, e.g., molded containers, blow molded containers, a sachet, a pouch, a tube, or any combination thereof.
- The dispensing port may be configured for a variety of applications including, topical, oral, sub-lingual, ocular, oraticular, and for inhalation. The dispensing port may be of a variety of forms, including, e.g., a jet nozzle, a spray nozzle, or a topical applicator such as a brush or sponge.
- Pressure sources other than CO2 cartridges may be used, including pressure sources wherein pressure results from a chemical reaction.
- In some embodiments, the disclosed dispenser includes multiple primary containers containing the same or different beneficial agents. In other embodiments, the primary container comprises multiple compartments that can be manually or automatically merged prior to administration. In some embodiments, a first compartment comprises an active ingredient in dry format and a second compartment comprises a diluent, and the two compartments are merged prior to administration to allow the two substances to reconstitute and form the beneficial agent. The disclosed dispenser may comprise multiple primary containers, with the contents of each being dispensed through a common dispensing port. In some configurations, the disclosed dispenser includes multiple primary containers, the content of each is dispensed from a different dispensing port
-
FIG. 1 a illustrates anintranasal dispenser 100 according to various embodiments described herein.Intranasal dispenser 100 can include abody 111, acap 113 attached to thebody 111 at aproximal end 114, and anactivation handle 112. Theactivation handle 112 communicates with an activation mechanism 102 (FIG. 1 b ). -
FIG. 1 b illustrates a cross section view of theintranasal dispenser 100 taken alongline 1b-1b shown inFIG. 1 a . Thedispenser 100 includes a pressure chamber 110 within thebody 111. Thedispenser 100 further includes a CO2 cartridge 121, wherein a distal end confronts a rupturingpin 122. The distal end of thecartridge 121 communicates with anactivation mechanism 102, which can be manipulated by thehandle 112. Apiston 125 defines a proximal end of the pressure chamber 110 and is moveable between a pre-activation position (shown inFIG. 1 b ) and an activated position (shown inFIG. 2 b ). A firstprimary container 123 is located in the pressure chamber 110 and is connected to thepiston 125. As noted previously, more than oneprimary container 123 can be located within thebody 111, thoughFIG. 1 b shows a singleprimary container 123. As shown inFIG. 1 b , theprimary container 123 is a blister pack made of a formed side, a lid, a flat side, and afitment 124. The formed side and the lid side are peripherally sealed to each other, and each to thefitment 124 to form a sealed compartment. Thefitment 124 is accommodated in an opening in thepiston 125 in a seal tight fashion viaseal 126. Apiston seal 128 maintains a sealed connection between thepiston 125 and thebody 111. Ventingwindows 127 prevent pressure from building in the proximal end of thebody 111. At the proximal end of thedispenser 100, a dispensing port 132 (shown inFIG. 1 b in the form of a two-prone nasal applicator) extend from thebody 111. Atube 131 runs inside the dispensingport 132 and communicates between the interior of thebody 111 and the proximal end of the dispensingport 132.Cap 113 provides at least one of physical protection and aseptic enclosure to thedispensing port 132. -
FIG. 2 a illustrates theintranasal dispenser 100 in an activated position. To reach this configuration, thehandle 112 is rotated away from thebody 111 to draw back theactivation mechanism 102, then depressed toward thebody 111 to cause theactivation mechanism 102 to rupture the CO2 cartridge 121 against the rupturingpin 122 and thereby pressurize the pressure chamber 110. Thecap 113 is removed to expose thedispensing port 132. - In
FIG. 2 b theactivation mechanism 102 advances the CO2 cartridge 121 such that the rupturingpin 122 is penetrated into thecartridge 121, allowing the CO2 gas to pressurize the pressure chamber 110. The pressure advances thepiston 125 toward the proximal end of thedispenser 100, to the activated position, causing the distal end of thetube 131 to penetrate theprimary container 123, allowing the pressure to depress theprimary container 123 and expel the content of theprimary container 123 through thedispensing port 132. Theseal 128 shows in theventing window 127, indicating that thedevice 100 has been actuated. - In some embodiments, a bleed hole opens when the
seal 128 reaches the activated position, allowing the gas from the pressure chamber 110 to deplete and reduce the pressure. In some embodiments, a piston return spring (not shown) is disposed in vented chamber 130 (FIG. 1 b ), and the arrangement is such that after activation, when the pressure in the pressure chamber 110 is depleted under a certain threshold pressure, the spring force overcomes the force applied by the pressure in the pressure chamber 110, causing thepiston 125 to retract and detach from thepiston seal 128. The bleed hole serves as a timer for the piston dwelling time at the activated position such that faster bleed (e.g. larger bleed hole) will reduce the pressure in the pressure chamber 110 faster and the spring to retract thepiston 125 earlier. The movement of thepiston 125 from the pre-activation position to the activated position and back provides a tactile sensation to the user of thedispenser 100 from beginning to end. The bleeding of the pressure from the pressure chamber 110 provides the user with an audible sensation of the dispensing process from beginning to end. The ordinarily skilled artisan will recognize that a variety of dispensing devices can be accommodated at the proximal end of the dispensing port, such as a jet nozzle and a spray nozzle. -
FIGS. 3 a and 3 b illustrate anintranasal dispenser 300 similar to theintranasal dispenser 100, comprising atelescopic body 301. Atether 304 is attached to thecap 303 on one end and acarabiner 305 on its other end.FIG. 3 a illustrates thedispenser 300 when the body is collapsed which may be more convenient for storage. By holding thetelescopic body 301 and pulling thetether 304 in the opposite direction of thebody 301, the telescopic body extends in an axial direction while thecap 305 is removed to expose the dispensingport 321, as shown inFIG. 3 b . The arrangement is such that the proximal end of thetelescopic body 301 covers the distal end of the cap, preventing the cap from being removed until thebody 301 is extended. At the extended position thehandle 312 is allowed to move to the armed position for activation. Thetether 304 is printed with information to facilitate user training and operation. The distal portion of thebody 301 is color coded to distinguish thedispenser 300 from other dispensers of different medications. In similar fashion, at least one of thetether 304, thecap 303, and thecarabiner 305 can be color coded. Moreover, thedistal end 302 of thebody 301 can have a distinguished shape to help identify the treatment. Thedispenser 300 facilitates operation of thedispenser 300 with limited dexterity or when wearing gloves as theextended body 301 provides better gripping of the device, and thetether 304 with thecarabiner 305 allows for easier holding and pulling than holding thecap 303 directly. For single hand operation, thecarabiner 305 can be attached to a firm object such as a garment, a carrying case or a bag, and the extension of thebody 301 is done by merely pulling thetelescopic body 301. Details of the treatment can be printed on or attached to at least one of thetether 304,carabiner 305, or thecap 303. Thecarabiner 305 can be attached to the garment of a subject to indicate that the subject has been treated. - From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
- Although the technology has been described in language that is specific to certain structures and materials, it is to be understood that the invention defined in the appended claims is not necessarily limited to the specific structures and materials described. Rather, the specific aspects are described as forms of implementing the claimed invention. Because many embodiments of the invention can be practiced without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended.
- Unless otherwise indicated, all number or expressions, such as those expressing dimensions, physical characteristics, etc., used in the specification (other than the claims) are understood as modified in all instances by the term “approximately”. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the claims, each numerical parameter recited in the specification or claims which is modified by the term “approximately” should at least be construed in light of the number of recited significant digits and by applying rounding techniques. Moreover, all ranges disclosed herein are to be understood to encompass and provide support for claims that recite any and all sub-ranges or any and all individual values subsumed therein. For example, a stated range of 1 to 10 should be considered to include and provide support for claims that recite any and all sub-ranges or individual values that are between and/or inclusive of the minimum value of 1 and the maximum value of 10; that is, all sub-ranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 5.5 to 10, 2.34 to 3.56, and so forth) or any values from 1 to 10 (e.g., 3, 5.8, 9.9994, and so forth).
Claims (20)
1-21. (canceled)
22. A dispensing device for dispensing a beneficial agent comprising:
a pressurized fluid source configured to contain a pressurized fluid,
a pressure chamber with an internal volume and comprising a primary container adapted to store a beneficial agent, and
a fluid barrier between the internal volume and an ambient environment;
wherein a fluid pathway from the primary container is provided responsive to providing a pressurized fluid into the pressure chamber from the pressurized fluid source, and
wherein the pressurized fluid source is disposed through the fluid barrier such that an internal end of the pressurized fluid source is exposed to the internal volume and an external end of the pressurized fluid source is exposed to the ambient environment.
23. The dispensing device of claim 22 , wherein the pressurized fluid source comprises a canister configured to contain a pressurized fluid.
24. The dispensing device of claim 23 , wherein the pressurized fluid includes any of liquified carbon dioxide, carbon dioxide gas, nitrogen gas, and argon gas.
25. The dispensing device of claim 22 , wherein the internal end of the pressurized fluid source is configured to open to provide the pressurized fluid to the internal volume upon opening.
26. The dispensing device of claim 25 , wherein the internal end of the pressurized fluid source is configured to rupture to open.
27. The dispensing device of claim 22 , further comprising the primary container comprising a beneficial agent, and wherein the fluid pathway from the primary container is adapted to expel the beneficial agent through a dispensing port.
28. The dispensing device of claim 22 , wherein the pressurized fluid source is configured to move relative to the fluid barrier from a first position where the internal end is unopened to a second position where the internal end is opened to provide the pressurized fluid to the internal volume.
29. The dispensing device of claim 22 , wherein the ambient environment includes an activation mechanism confronting the external end and configured to actuate the pressurized fluid source upon actuation.
30. The dispensing device of claim 29 , wherein the actuation of the pressurized fluid source brings the internal end into an interaction with a fluid source opening element such that the internal end opens to provide the pressurized fluid to the internal volume.
31. The dispensing device of claim 30 , wherein the internal end includes a rupturable membrane, and the fluid source opening element comprises a rupturing pin configured to rupture the rupturable membrane.
32. The dispensing device of claim 29 , wherein the activation mechanism is configured to prevent movement of the pressurized fluid source away from the internal volume of the pressure chamber.
33. The dispensing device of claim 22 , wherein the pressurized fluid source comprises an abutment feature configured to prevent movement of the pressurized fluid source away from the internal volume of the pressure chamber.
34. The dispensing device of claim 22 , wherein the fluid barrier comprises any of a seal, an o-ring, or a tight fit between the fluid barrier and at least a section of the pressurized fluid source.
35. The dispensing device of claim 22 , further comprising a connecting section of the pressurized fluid source connecting the internal end to the external end, wherein the fluid barrier is configured to seal against the connecting section.
36. The dispensing device of claim 22 , wherein the internal volume contains a dispensing assembly.
37. The dispensing device of claim 36 , wherein the dispensing assembly includes piston configured to move when a pressurized fluid is provided to the internal volume.
38. The dispensing device of claim 22 , wherein the pressurized fluid source is configured to move in an axial direction relative to the fluid barrier.
39. The dispensing device of claim 22 , further comprising a bleed path configured to controllably release the pressurized fluid from the internal volume of the pressure chamber.
40. The dispensing device of claim 39 , wherein the fluid barrier is configured to provide the bleed path responsive to the pressurized fluid source providing a pressurized fluid to the internal volume of the pressure chamber.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/189,129 US20230338675A1 (en) | 2018-10-23 | 2023-03-23 | Pressure barrier drug delivery device |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862749296P | 2018-10-23 | 2018-10-23 | |
US16/661,824 US11638794B2 (en) | 2018-10-23 | 2019-10-23 | Intranasal pressure drug delivery device |
US18/189,129 US20230338675A1 (en) | 2018-10-23 | 2023-03-23 | Pressure barrier drug delivery device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/661,824 Continuation US11638794B2 (en) | 2018-10-23 | 2019-10-23 | Intranasal pressure drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230338675A1 true US20230338675A1 (en) | 2023-10-26 |
Family
ID=70281119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/661,824 Active 2041-01-06 US11638794B2 (en) | 2018-10-23 | 2019-10-23 | Intranasal pressure drug delivery device |
US18/189,129 Abandoned US20230338675A1 (en) | 2018-10-23 | 2023-03-23 | Pressure barrier drug delivery device |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/661,824 Active 2041-01-06 US11638794B2 (en) | 2018-10-23 | 2019-10-23 | Intranasal pressure drug delivery device |
Country Status (5)
Country | Link |
---|---|
US (2) | US11638794B2 (en) |
EP (1) | EP3870258A4 (en) |
JP (1) | JP2022505636A (en) |
CN (1) | CN113226418B (en) |
WO (1) | WO2020086752A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3274021B1 (en) | 2015-03-24 | 2024-02-14 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
WO2020086752A1 (en) | 2018-10-23 | 2020-04-30 | Aktivax, Inc. | Intranasal pressure drug delivery device |
CA3145580A1 (en) | 2019-08-09 | 2021-02-18 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
US12268847B1 (en) | 2021-02-10 | 2025-04-08 | Kaleo, Inc. | Devices and methods for delivery of substances within a medicament container |
FR3124735B1 (en) * | 2021-07-05 | 2023-06-16 | Aptar France Sas | Nasal dispensing device for fluid product |
US20240335617A1 (en) * | 2021-07-29 | 2024-10-10 | Aktivax, Inc. | Administration device with detachable indicium |
WO2023081411A1 (en) * | 2021-11-05 | 2023-05-11 | Vyaire Medical, Inc. | Compressed gas nebulizer |
WO2023122619A1 (en) * | 2021-12-20 | 2023-06-29 | Aktivax, Inc. | Delivery device for a multi-component beneficial agent by intranasal and other routes |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
CN117571979B (en) * | 2024-01-15 | 2024-03-19 | 佳木斯大学 | Premature rupture detection kit for fetal membranes for obstetrics and gynecology department |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013050A (en) * | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
US20020056760A1 (en) * | 2000-09-25 | 2002-05-16 | Evit Labs | Shock wave aerosolization method and apparatus |
US20140066846A1 (en) * | 2010-11-08 | 2014-03-06 | Aktivpak, Inc. | Beneficial agent dispenser |
US9259539B2 (en) * | 2005-02-01 | 2016-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
WO2016058009A2 (en) * | 2014-10-06 | 2016-04-14 | Aktivax | Auto-injector |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB662943A (en) * | 1948-01-30 | 1951-12-12 | Becton Dickinson Co | Injection device |
US3308818A (en) * | 1964-07-24 | 1967-03-14 | Eugene V Rutkowski | Injection cartridge |
US3733010A (en) * | 1971-04-30 | 1973-05-15 | Ciba Geigy Corp | Air pressure operated dispenser |
US3788526A (en) * | 1973-02-12 | 1974-01-29 | Ciba Geigy Corp | Compressed air operated dispenser with mechanical force multiplying means |
US6056716A (en) * | 1987-06-08 | 2000-05-02 | D'antonio Consultants International Inc. | Hypodermic fluid dispenser |
GB9109064D0 (en) * | 1991-04-26 | 1991-06-12 | Dunne Miller Weston Ltd | Dispensing device |
US5349947A (en) * | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
AUPN976496A0 (en) * | 1996-05-10 | 1996-05-30 | Glaxo Wellcome Australia Ltd | Unit dose dispensing device |
EP0888790A1 (en) * | 1997-07-04 | 1999-01-07 | PowderJect Research Limited | Drug particle delivery device |
US6045534A (en) * | 1997-10-27 | 2000-04-04 | Sarcos, Inc. | Disposable fluid injection module |
US6125844A (en) * | 1998-04-30 | 2000-10-03 | Westwood Biomedical | Portable oxygen based drug delivery system |
US6210359B1 (en) * | 2000-01-21 | 2001-04-03 | Jet Medica, L.L.C. | Needleless syringe |
EP1280611A1 (en) * | 2000-05-11 | 2003-02-05 | Crown Cork & Seal Technologies Corporation | Dispensing pump |
ATE473023T1 (en) | 2001-11-09 | 2010-07-15 | Alza Corp | PNEUMATICALLY DRIVEN AUTO INJECTOR |
GB2410190A (en) * | 2004-01-26 | 2005-07-27 | Medical House Plc | Disposable gas-powered needle-free injection device |
NZ560516A (en) * | 2005-02-01 | 2010-12-24 | Intelliject Inc | A delivery system where a medicant is automatically delivered on activation as well as a recorded instruction |
JP4697398B2 (en) | 2005-02-22 | 2011-06-08 | 藤森工業株式会社 | Preparation kit for injection and syringe containing medicine |
US20070055200A1 (en) * | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Needle-free jet injection drug delivery device |
US8579856B2 (en) * | 2007-05-16 | 2013-11-12 | Mystic Pharmaceuticals, Inc. | Unit dose drug delivery platform |
JP5252890B2 (en) * | 2007-11-16 | 2013-07-31 | キヤノン株式会社 | Drug delivery device |
WO2011094025A1 (en) * | 2010-02-01 | 2011-08-04 | Becton, Dickinson And Company | Low dose prefilled drug delivery device and method |
GB201313782D0 (en) * | 2013-08-01 | 2013-09-18 | Oval Medical Technologies Ltd | Drug delivery device |
US10124930B2 (en) * | 2014-05-24 | 2018-11-13 | Sessions/Painter, Llc | Pull-out expandable contractible pour spout cartridge insert for liquid container openings |
US10300228B2 (en) | 2014-08-26 | 2019-05-28 | Innovosciences, Llc | Thermal modulation of an inhalable medicament |
KR101978554B1 (en) | 2016-05-17 | 2019-05-16 | 한양대학교 산학협력단 | Drug Delivery Device for nasal cavity to brain |
US10029054B2 (en) | 2016-06-22 | 2018-07-24 | Clover Hill Healthcare, Inc. | Lower body cavity treatment methods and devices using carbon dioxide and saline |
WO2020086752A1 (en) | 2018-10-23 | 2020-04-30 | Aktivax, Inc. | Intranasal pressure drug delivery device |
-
2019
- 2019-10-23 WO PCT/US2019/057714 patent/WO2020086752A1/en unknown
- 2019-10-23 EP EP19876316.1A patent/EP3870258A4/en active Pending
- 2019-10-23 US US16/661,824 patent/US11638794B2/en active Active
- 2019-10-23 JP JP2021522047A patent/JP2022505636A/en active Pending
- 2019-10-23 CN CN201980080403.2A patent/CN113226418B/en active Active
-
2023
- 2023-03-23 US US18/189,129 patent/US20230338675A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013050A (en) * | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
US20020056760A1 (en) * | 2000-09-25 | 2002-05-16 | Evit Labs | Shock wave aerosolization method and apparatus |
US9259539B2 (en) * | 2005-02-01 | 2016-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US20140066846A1 (en) * | 2010-11-08 | 2014-03-06 | Aktivpak, Inc. | Beneficial agent dispenser |
WO2016058009A2 (en) * | 2014-10-06 | 2016-04-14 | Aktivax | Auto-injector |
Also Published As
Publication number | Publication date |
---|---|
EP3870258A4 (en) | 2022-08-10 |
WO2020086752A1 (en) | 2020-04-30 |
EP3870258A1 (en) | 2021-09-01 |
US20200121871A1 (en) | 2020-04-23 |
JP2022505636A (en) | 2022-01-14 |
US11638794B2 (en) | 2023-05-02 |
CN113226418B (en) | 2023-12-01 |
CN113226418A (en) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230338675A1 (en) | Pressure barrier drug delivery device | |
US8210167B2 (en) | Manually operated monodose nasal sprayer | |
AU683905B2 (en) | Device for administering pharmaceutical substances | |
JP4504688B2 (en) | casing | |
US6145703A (en) | Spray applicator | |
US5746728A (en) | Fluid pump without dead volume | |
TWI544939B (en) | Ergonomic hand-operable fluid-dispensing device | |
US20100095957A1 (en) | Manually operated monodose nasal sprayer device | |
EP2637716B1 (en) | Beneficial agent dispenser | |
US20120241465A1 (en) | Dispensing device along with method for dispensing product | |
US20080210228A1 (en) | Monodose nasal sprayer | |
US20130324948A1 (en) | Cotton balls, cotton swabs and cotton swab holder | |
SK280177B6 (en) | DOSING DEVICE FOR DRAIN DRAIN ONE D | |
WO2004014778A3 (en) | Container and valve assembly for storing and dispensing substances, and related method | |
JPH0794265B2 (en) | Refillable container | |
US8960425B2 (en) | Nasal spray and tissue dispenser | |
US12151925B2 (en) | Dispenser actuator assembly | |
US2971509A (en) | Disposable hypodermic syringe | |
JP2622309B2 (en) | Sprayer | |
WO2023122619A1 (en) | Delivery device for a multi-component beneficial agent by intranasal and other routes | |
EP2786942B1 (en) | Single dose fluid dispenser package | |
US7475438B2 (en) | Portable bidet | |
CN219440286U (en) | Inhalers and Protective Devices | |
WO2016147859A1 (en) | Sealing container | |
JP4620463B2 (en) | Aerosol dispenser and adapter used for it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AKTIVAX, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENOSAR, AMIR;REEL/FRAME:063082/0881 Effective date: 20191014 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |